Professor
University of Alabama at Birmingham
Mountain Brook, Alabama, United States
W. Timothy Garvey is the Butterworth Professor and University Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham. Dr Garvey obtained his medical degree from Saint Louis University, completed residency training in internal medicine at Barnes Hospital, Washington University, and was a clinical fellow in endocrinology and metabolism at the University of Colorado Health Sciences Center and University of California, San Diego School of Medicine. Dr Garvey has achieved international recognition for his research in the metabolic, molecular and genetic pathogenesis of insulin resistance, type 2 diabetes and obesity. The Garvey laboratory has made important observations regarding the pathogenesis of human insulin resistance and has furthered understanding of the role of the glucose transport system in human insulin resistance. He has authored over 300 publications, and is the Director/PI of the NIH-funded Diabetes Research Center at UAB
A further interest concerns the understanding of obesity as a disease and advancing medical models to improve care of patients with obesity. Dr Garvey has been the lead author on the American Association of Clinical Endocrinology (AACE) Clinical Practice Guidelines for Obesity, coauthor of the AACE diabetes and NASH guidelines and AACE/ASMBS/TOS bariatric surgery guidelines, and co-author on the 2019 ADA nutrition recommendations. He authored the position statement affirming Adiposity-Based Chronic Disease (ABCD) as the diagnostic term for obesity which has been endorsed by both AACE and the European Association for the Study of Obesity (EASO). He has proposed a medically actionable classification system (ICD codes) for ABCD and has helped address the rational use of newer second-generation obesity medications within the context of a complications-centric approach to obesity care. He has established Cardiometabolic Disease Staging (CMDS) for risk prediction of both type 2 diabetes and cardiovascular disease to guide the intensity of preventive interventions. He is an elected member of ASCI and AAP and Master of the American Association of Clinical Endocrinology and the American Board of Obesity Medicine.
Disclosure information not submitted.
The Past, Present, and Future of Obesity Management
Saturday, May 11, 2024
10:45 AM – 12:00 PM CDT